The clinico-pathological databases analysis showed that HER2 upregulation and PR downregulation were associated with high CHRNA6 expression, and BRCA1/2 mutation was associated with low CHRNA6 expression, suggesting that CHRNA6 may be a potential diagnostic biomarker in breast cancer. Here, ERBB2 is linked to breast carcinoma.